<DOC>
	<DOC>NCT02381158</DOC>
	<brief_summary>This is a single-centre, open label study, aiming to evaluate the efficacy of beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg nebulized), on airway resistance and reactances (measured with Rint and FOT techniques) in children with recurrent wheezing, aged 2-5 years. In addition, clinic score as frequency of symptoms and exacerbations, will be assessed.</brief_summary>
	<brief_title>Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Informed and subscribed consent before any procedure Age range : 2 ≤5 years Male and female patients Recurrent wheezing affected ( ≥ 4 episodes in the last 12 months) PAI positive (at least one primary and two secondary ): Primary: 1. one parent with asthma 2. Atopic Dermatitis 3. sensibilisation to air allergen Secondary: 1. Food sensibilization 2. wheezing also not during the infective episodes 3. eosinophilia (&gt;4%) story of severe wheeze requiring hospitalization treatment with inhaled glucocorticoids during the previous 4 weeks or with oral glucocorticoids in the previous 8 weeks structural abnormalities of the lungs (tracheobronchial bronchomalacia, external compressions, etc) Persistent infections aspiration lung disease (gastroesophageal reflux disease, etc.) Cystic fibrosis prematurity or bronchopulmonary dysplasia Tuberculosis primary ciliary dyskinesia congenital heart disease pulmonary foreign body bronchiectasis Immunodeficit</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wheezing</keyword>
	<keyword>Children</keyword>
</DOC>